SEN"
`
`COMPANY PROFILE
`
`
`
`PAGE 1 OF 18
`
`LUPIN V SENJU
`
`IPR20l5-01105
`
`

`
`President’s Message
`
`The characters that comprise Senju's company name in the Japanese language are “Sen” and "Ju', which
`
`literally mean ‘thousand’ and ‘bringing happiness”, respectively. Senju, bringing much (a thousand)
`
`happiness. has an objective to bring a “happiness” to the people associated with us through the
`
`development of original pharmaceutical products for the care of the five senses (eyes. ears, nose. throat
`
`PtecidaafuMcuagc
`
`and skin), which ultimately Improves the joy of living.
`
`This is our management policy; “Good Company‘.
`
`We strongly believe that Senju should be a trustworthy and essential company by putting ourselves into the
`
`other person's shoes and acting under the Action Guideline; ‘if I were you".
`
`Yukoh Yoshida
`Preddent & cso
`
`/""‘”“~—_.
`
`PAGE 2 OF 18
`
`

`
`
`
`
`
`£299.]zuauuzflruuw
`
`Management Policy
`
`Good Company
`
`At Senju Pharmaceutical, our mission is to pursue happiness
`
`for every person associated with the company.
`“Being a good company" is our management policy.
`As a company that aims to be reliable, necessary, and valuable to society, we are
`committed to pursuing happiness for all people associated with the company. rather than
`simply becoming a ‘Big Company” that pursues only greater growth and increased sales.
`
`Action Guideline
`
`If I were you
`
`“If I were you"
`Considering others’ viewpoints is the starting point for all of our business activities.
`We should not do to others what we would not like to be done to us.
`
`To treat others in a way that would make us happy if we were treated that way. we
`need to think about and do things from others’ points of view at all times.
`These are the action guidelines that Senju Pharmaceutical employees aim to follow.
`
`SéNU SENSE
`
`SENJU SENSE is a systematic collection of the concepts and values that have
`been carefully handed down over the generations since the founding of our
`company, including our Management Policy ‘Good Company”. It is a collective
`name for Senju‘s values, which are so essential during decision-making and the
`execution of our responsibilities. By ensuring that each and every employee
`shares our SENJU SENSE and works with finn belief in the pursuit of happiness
`for all people associated with the company, we aim to come up with a variety of
`innovative new ideas, thereby ensuring that Senju remains a ‘Good Company".
`
`
`
`PAGE 3 OF 18
`
`

`
`Ethical Products
`for Medical Professionals
`
`As a manufacturer of ophthalmological drugs, Senju Pharmaceutical
`
`has entered the promising fields on the front lines of medicine.
`
`
`
`PrescriptionProducts
`
`
`
`In addition to creating new medicines, particularly
`
`ophthalmicsolutions in thefield ofeye medicine, Senju
`
`Pharmaceutical offers a broad range of generic products
`
`and we steadily implement measures to respond to
`
`changes in the market environment. What's more. we
`
`also work hard to develop and promote what's referred to
`
`as “orphan drugs‘, which treat rare diseases suffered by
`extremely small numbers of patients.
`Senju Pharmaceutical will take on new challenges every
`
`day with the aim of “maintaining and improving vision” for
`
`as many patients as possible by increasing the added
`
`value of our products by strengthening the infonnation
`gathering and communication capabilities we have built
`up over many years in the field of ophthalmology and by
`accurately identifying treatment needs in the medical
`workplace as well as by enhancing our marketing, sales
`and logistics functions for promoting activities to
`encourage the rapid popularization of our products.
`
`PAGE 4 OF 18
`
`‘
`
`0
`
`=
`' =
`
`‘I
`_
`
`:
`' 5. i
`-"
`i .‘ _ f _
`rt
`‘
`j ‘
`_"m
`
`v
`
`i
`fl
`__
`
`

`
`M M 8 (Medical Management Supporter)
`
`For Human, for Medical, for Tomorrow.
`
`
`
`SWN
`
`Senju Pharmaceutical has developed an MMS
`
`(Medial Management Supporter) business to provide
`
`various types of support for the operation of eye
`
`clinics with the aim of contributing to healthcare in
`local communities.
`
`Strong clinic management is essential to providing
`
`high-quality health-care.
`
`Through MMS we provide support to the many
`
`management challenges faced by ophthalmologists,
`
`including the handling of reforms to various systems.
`
`labor management, the fostering of human resources.
`
`the handling of tax issues, building partnerships with
`
`other facilities, and improving patient satisfaction.
`
`What's more, in order to provide ever-changing
`
`healthcare information to ophthalmologists on a
`
`timely basis, we provide information via management
`magazine Medi-Net and our ophthalmologists‘
`
`management information service website.
`
`PAGE 5 OF 18
`
`
`
`Management magazine Medi-Net
`
`Architectural models
`
`

`
`
`
`OvertheCounter(OTC)Products
`
`
`
`
`
`Over the Counter (OTC) Products
`
`The Mytear brand was developed from our research into tears.
`
`
`
`Tears are invaluable to our eyes and they have even
`
`is an over-the-counter product containing
`
`been described as "heaven's eye medicine".
`
`pranoprofen, a nonsteroidal anti-inflammatory drug
`
`Thanks to our ongoing efforts in tear research, in
`
`that has been recognized as an effective and safe
`
`1965 Senju Pharmaceutical launched Japan's first
`
`prescription product.
`
`ever tear-type eye medicine, the artificial tear
`
`Mytear.
`
`Fifteen years later in 1980 we launched Mytear CL
`
`as a contact lens use eye medicine, the first in
`
`Japan that could be applied while still wearing soft
`
`contact lenses. We have continued to develop eye
`
`medicine under the Mytear brand in response to
`
`changing times and changing user needs.
`
`In recent years. we have utilized our product
`
`development capabilities as a manufacturer of
`
`prescription eye medicine and our many years of
`
`marketing experience to launch unique and high
`
`quality products, including Mytear EYETECT, which
`
`PAGE 6 OF 18
`
`
`
`

`
`Overseas Activities
`
`When it comes to eye health and the development of
`
`pharmaceutical products, there are no national borders.
`
`
`
`i
`
`
`
`suing/tins‘;$l3n3.\0
`
`Senju Pharmaceutical promotes international
`
`SCIENCE 8. TECHNOLOGY (BEIJING) CO.. LTD.
`
`activities with an eye on the pharmaceutical products
`
`and local manufacturing and sales company SENJU
`
`of tomorrow, beyond the limits of individual countries
`
`WANHE PHARMACEUTICAL (SHENZHEN) CO., LTD.
`
`or companies.
`
`As we approach the global age, Senju
`PharmaceuticaI's overseas activities have become
`
`more diverse than ever. We have promoted the export
`
`of finished products. new product technology and
`patent derivations. and we are now active in more
`
`than 50 countries. In order to build partnerships and
`
`introduce the latest technologies and information as
`
`quickly as possible, it is necessary to remain
`
`unconstrained by regional location, industry or scale.
`In the United States, we have established a
`
`subsidiary SENJU USA. INC. with the aim of
`
`promoting research and development in United
`
`States pharmaceutical products. In China, we have
`
`established subsidiary SENJU PHARMACEUTICAL
`
`We are actively seeking to expand the scope of our
`activities and have established local offices in Russia
`
`and Vietnam.
`A‘
`
`-4..
`
`
`
`PAGE 7 OF 18
`
`

`
`Research and Development
`
`We are using our cutting edge technology and unique research
`
`system to pursue the limitless possibilities of people and science.
`
`
`
`ResearchandDevelopment
`
`“All things in nature have a reason for being.
`Today's common sense is not common sense tomorrow.’
`This is the motto of our researchers.
`
`research into the creation of treatments by using cutting
`
`edge technology to identify the molecules that cause eye
`
`diseases. At our Kobe Creative Center, we promote
`
`Senju Pharmaceutical pursues research and development
`
`research that will lead directly to product development.
`
`through flexible thinking without being constrained by
`existing limits or stereotypes through our unique research
`
`including accumulating the data needed for the approval of
`phannaceutical products. Al of our centers work in close
`
`system, which includes intemationd joint research projects
`
`cooperation on this research. Our eyes are fixed firmly on
`
`and collaborative research with industry and academia.
`
`the future. Our goal and aspiration is to develop the
`
`At the Senju Laboratory of Ocular Science and our Oregon
`
`phamiaceutical products that are tidy needed by society,
`
`Laboratory in the United States, we carry out basic
`
`safely and as quicldy as possible.
`
`I Kobe Creative Center
`
`I Senju Laboratory of Ocular Science
`
`IOregon Laboratory, United States
`
`
`
`PAGE 8 OF 18
`
`

`
`Production
`
`Bringing you high quality pharmaceutical products from
`
`factories that meet PIC/S GMP standards
`
`
`
`When manufacturing pharmaceutical products, it is
`
`standards at an early stage in anticipation of revisions to
`
`essential to comply with the GMP (Good Manufacturing
`
`GMP standards. Moreover, we have built a system that
`
`Practice) standard for the manufacture of phannaceutical
`
`allows us to implement ongoing improvements to reduce
`
`urrpsnprud
`
`products and quasi dmgs, from delivery of raw materials
`
`our impact on the environment.
`
`through to shipment of the finished product.
`
`Whats more. because eye medicine is a sterile product.
`
`We will continue to deliver a steady supply of high quality
`pharmaceutical products to Japan and the world from
`
`there is a need for sterile manufacturing facilities that
`
`factories that combine state-of-the-art manufacturing
`
`guarantee a high level of sterility, and a need for the
`
`facilities with a state-of-the-art manufacturing environment.
`
`installation of testing equipment and quality control.
`
`Senju Phannaceutical works to comply with PIC/S-GMP
`
`PIC/S: The Pharmaceutical Inspection Convention and
`Pharmaceutical Inspection Co-operation Scheme
`
`I Manufacturing Plant Karatsu
`
`I Manufacturing Plant Fukusaki
`
`
`
`Status of lSO14001 Certification Acquisition : Plant Fukusaki in December 2007/ Plant Karatsu in December 2014
`
`PAGE 9 OF 18
`
`

`
`Animal Health
`
`Using the pharmaceutical technologies developed for
`
`humans to develop health products for companion animals
`
`
`medical advances have increased the length of time
`
`People are not the only living things to use sense
`
`organs such as the eyes and ears to collect
`
`abundant information for use in their everyday lives.
`
`Sense organs are also an essential part of the daily
`
`lives of the pets who live side by side with humans.
`
`In recent years, improved living standards and
`
`that pets and humans can live side by side, leading
`
`to increased risk from ageing associated lifestyle
`
`diseases and increased importance of the sense
`organs in pets‘ daily lives. Senju Pharmaceutical has
`continued to utilize the phannaceutical development
`technologies we have accumulated over many years
`of developing human sensory organ pharmaceutical
`products in the development and promotion of animal
`pharmaceutical products and other animal products,
`helping our pets to live long and happy lives.
`
`Ll
`
`‘ ‘
`rs
`
`a
`.1,“
`.
`*”"‘
`..... _ __
`I I .i.‘.'-. v
`
`.
`
`g
`‘(W _ ___~
`....""':—-a
`‘t\
`
`g.
`5
`
`PAGE 10 OF 18
`
`
`
`AnimalHealth
`
`

`
`Alleviation ar the Five Senses I
`
`PAGE 11 OF 18
`
`

`
`Allnuhrion or the F7»: Scum I
`
`
`
`SEND
`
`Senju Pharmaceutical Co., Ltd.
`
`2-5-8. Hirano-machi. Chuo-ku. Osaka
`
`TEL : 06-6201-2512 (main switchboard)
`FAX :06-6226-0406
`
`URL : http://www.senju.co.jp
`
`PAGE 12 OF 18
`
`

`
`Milestones in Our History
`
`$10113”
`
`1988
`
`1993
`
`1994
`1999
`
`21111
`
`2010
`
`2011
`2012
`
`2013
`2014
`
`June
`
`January
`February
`
`June
`April
`July
`April
`April
`April
`April
`April
`
`Cepitd inaeased to 1,415,500,000 yen.
`NSAJD Ophthdmic Sohtion, 'NlFLAN'. launched.
`Los Angeles Office opened it USA.
`Kobe Creative Center completed.
`Yokohama Branch opened.
`Kobe Branch opened.
`Chiba Brandi and Saltama Branch opened.
`NSAID Ophthdmlc Solution, 'BRONUCK', laundied.
`A laboratory completed in Oregon, USA.
`The European Otlice opened.
`Beijing Otlice opened in Chile.
`Seniu USA. hc.estab|shed.
`Senju Laboratory of Ocular Science, Kobe Laboratory
`oornpleted.
`Yukoh Yoshida becomes the President of the Company.
`Senju Medical Consulting (Shanghai) Co.. Ltd. established in
`Shanghai, China.
`Osaka Logistil Warehouse opened.
`Manufacturing Plant Karatsu bult at 4228-1 Ishishi,
`Karotsu-shi, Saga.
`Ophthalmic Solution tor Glaucoma Ocular Hypertension,
`'LUM|GAN'. launched
`Senju Phannaceutical Science & Technology (Beijing) co.
`Ltd. established.
`Hanoi Otlice opened in Hanoi, Vietnam.
`Ophthalmic Solution tor Glaucoma Ocular Hypertension.
`'AlPHAGAN'. launched.
`Moscow Office opened in Moscow, Russia.
`Saitama Office opened.
`Chiba Otlice opened.
`Shizuoka Satelite Otlice opened.
`Senfii Wanhe Phamaoeuticd Shenzhen Corp. estabished in
`Shenzhen, Chiia as a joint company.
`
`1947
`
`1949
`
`1 951
`
`1 953
`1 955
`1 957
`
`1958
`1960
`
`1961
`
`1962
`
`1963
`
`1964
`1965
`
`1967
`1969
`1 970
`1971
`
`1 972
`
`1973
`
`1 974
`
`1975
`1 978
`
`1980
`
`1981
`1983
`
`1984
`
`1 985
`1 987
`
`The company founded at 12-tshigatsuji-cho, Tennoji-ku,
`Osaka. Shrt-up capital of 195,000 yon. President, Hioshi
`TsuzukL
`Injection Produd for Neutropenia, 'PAMLT|N'. launched.
`Reishln Tanlmuro mcomes the President ot the Company.
`Company head office relomted to 2-42 Hirano-madtl,
`Higashi-ku, Osaka.
`Manufadurlng plant reheated to 432 twamrlo-cho, Ashiys City.
`Agreement oonduded with Takeda Pnannaoeuticd Company
`Limited for the sole distribution of Senju Products.
`Capitd increased to 780,000 yen.
`Masao Yoshida becomes the President of the Company.
`Capitd increased is 3,000,030 yen.
`Tokyo Branch opened.
`Ophthdmic Solution for Catarads. 'CATAUN‘. launched.
`Capitd increased to $000,000 yen.
`Implementation of the City Planning Act meant the company
`relocabd theAshiya Plant to a newly-bult plant at 416
`lwazono-cho.
`Fukuoka Branch opened.
`Capttd increased to 9,000,000 yen.
`Capitd increased to 13,500,000 yen.
`ltami Plant needy bull for the manufacture of ingredients at 1-1
`Oshika-Sakuragaoka. Itami City.
`Capital Increased to 18,000,000 yen.
`Laboratory and attached fadlflies newly built at the Ashlya
`Plant.
`Capital increased to 30,000,000 yen.
`Artificial Tear Ophthalnic Solutions, "MYTEAR', launched.
`Company head offiee relocated to 1-83 Doshin-cho. Kite-ku.
`Osaka.
`Nagoya Brandi opened.
`Capitd increased to 75,000,000 yen.
`Sendai Branch opened.
`Sapporo Branch opened.
`Laboratory completed in the ltarni Plant.
`company need office and Osaka Branch relocated to 3-28
`Hirano-rnachi, Higashi-ku, Osaka (Arnakasu Bulding).
`Hiroshima Branch opened.
`Capitd Increased to 150,0tl),000 yen.
`Maniufaduring Plant Fukusdti bull at 767-7 Kazuiranonishi,
`Saiji, Fukusaki-oho, Kanzaki-gun, Hyogo.
`Capital Increased to 225,000,000 yen.
`Shoji Yoshida becomes the President of the Company.
`company head office relocated to 3-6-1 Hirano-rnachl,
`Higashi-ku, Osaka (7" Floor oi Hlrano-machl Century Building).
`Ophttnlmic Solution for use on contact lens. 'MYTEAR CL‘.
`laundied.
`Capital increased to -t50.000.000 yen.
`A biologicd hboratory completed in the Itarni Research
`Laboratory.
`Capital increased to 1,050,000,000 yen.
`Utsunorniya Branch. Matsurnoto Branch, and Takamatsu
`Branch opened.
`Kyoto Branch opened.
`lntraocular krigating Solution, ‘OPEC-IUARD MA‘, lamched.
`
`Jill
`February
`September
`
`June
`
`§§§
`
`June
`
`February
`
`June
`
`January
`
`PAGE13OF18
`
`

`
`Company Profile
`
`Trade Name
`Principal Offioe
`
`Senju Phannaceutical C0,. Ltd.
`2-5-8, Hirano-machi. chuo-ku, Osaka. 541-0046. Japan
`TEL: +81-6-6201-2512
`FAX: +81-6-6226-0406
`
`Date of Incorporation April, 1947
`Representative
`Yukoh Yoshida
`Capital
`1.4 billion yen
`Employees
`861 (as of March 2015)
`Sales
`35 billion yen (as of March 2015)
`Accounting Period
`March
`Business Content
`(1) Pharmaceutical business: manufacture and sale of prescription eye, ear,
`nose and throat medicines. contact lens solutions and animal medicines
`(2) other business: manufacture and sale at raw materials for cosmetics
`
` sigma
`
`.iu:dwrr_)
`
`I Matters related to officers
`
`Member of the Board of Directors
`
`Executive Officer
`
`Shoji Yoshida
`Yukoh Yoshida
`Shuhei Yoshida
`
`M"5”V°5hi Azuma
`
`Takeshi Masuda
`
`Akemi Yamasaki
`
`Chairman of the Board
`President 8. CEO
`Executive Vice President & C00
`”°““ °‘ °°'”°"‘° “°"°9°"‘°"‘ D""‘l°“ 3”“ “"9” SW“ °“'"l°"
`Ma"a9i"9 E"°"fi"° °ffi°°'
`Head of Laboratory, Senju Laboratory of Ocular Science
`Managing Excutive Officer
`Head of Phannaceuticd Marketing Division
`Corporate Auditor
`
`Takeshi Sugisawa Head of Business Development Division
`Hidemi Shimoji
`Head of Research and Development Division
`Mikio Ogawa
`Head of Overseas Business Division
`Tomio Maenaka
`Head of Production Division
`Michinari Wada
`Head of Reliability Assurance Division
`_
`Takahiro Ogawe
`President of SENJU USA (secondment)
`
`ITrends in Sales and Current Profits
`
`Current Profits (unit: I billion)
`9.0
`8.0
`7.0
`6.0
`5.0
`4.0
`3.0
`2.0
`1.0
`0
`
`Sales (unit: ¥ billion)
`35.0
`
`30.0
`
`25.0
`
`20.0
`
`
`
`2010
`
`2011
`
`2012
`
`2013
`
`2014
`
`Sales(unlt: ¥ billion) :0: Current Profits (unit: ¥ billion)
`
`
`
`4.4
`
`2.6
`
`5.1
`
`7.4
`
`Unit “on ya"
`
`Current profits
`
`3.0
`
`PAGE 14 OF 18
`
`

`
`
`
`(rnuuo)333930
`
`
`
`.'-1'11.-IKJHA.K.\I‘v.‘aiW(ZJ.‘xiTN.’-IS‘
`
`Offices (Overseas)
`
`I Laboratories and Offloes
`
`.SEN.IU LABORATORY OF OCULAR SCIENCES (SLO5)
`OTRADI Bioscience Incubator, 4640 SW Macadam Ave., Suite 2000, Portland, OR 97239, U.S.A.
`Tel: +1-503-748-6202
`Fax: +1-503-748-5204
`Osizruu PHARMACEUTICAL 00.. LTD. BEIJING OFFICE
`Unit 3602. Fortune Plaza Office Tower A, No. 7 Dongsanhuan Zhonglu, Chaoyang District, Beijing, 100020 P.R.C
`Tel: +86-10-6533-0200
`Fax: +86-10-6536-1329
`
`CSENJU PHARMACEUTICAL 00.. LTD. Hanoi Repruentatlvo Office
`Room 1314, Level 13, Ha Noi Towers, 49 Hal Ba Trung, Hoen Klem District, Ha Noi. Vietnam
`Tel: +84-4-8934-3890
`Fax: +84-4-3934-3966
`
`Owloscow Representative office at Sonju Pharmaceutical 00.. Ltd.
`Office No.105. 1st tloor. str. 6, dom 1A. Tretiy Nizhneiikhoborskiy proyezd. Moscow 125371. Russian Federation
`
`I Subsidiaries
`
`.SEN.lU USA, INC.
`21700 Oxnard Street. Suite 1070 Woodland Hills. CA 91367. U.S.A.
`Tel: +1-818-719-7190
`Fax: +1£18-719-7195
`CSENJU PHARMACEUTICAL SCIENCE It TECHNOLOGY (BEIJING) 00., LTD.
`Unit 3602. Fortune Plaza Office Tower A. No. 7 Dongsanhuan Zhongiu. Chaoyang District. Beijing. 100020 P.R.c
`Tel: +86-10-6533-0200
`Fazc +86-10-6536-1329
`
`QSENJU WANHE PHARMAcEU1IcAL(sHENzNEN) co.. LTD.
`Block B. Wenhe Technology Complex. HI-tech Perk. Guangmlng District. Shenzhen, Guangciong Province, China
`
`
`
`PAGE 15 OF 18
`
`

`
`
`
`(urduf)$33350
`
`OffiCCS (Japan)
`
`I Head Office
`
`Hirano-machi Century Building
`2-5-8. Hirano-machi, Chuo-ku, Osaka. 541-0046
`
`TEL: +81-6-6201-2512 (main switchboard) FAX: +81-6-6226-0406
`
`I Branches and Groups
`
`[Northern Japan Branch]
`.s‘PP°'° °"'°°- 5°PP°'° G'°"P
`T3'<°d= 39PP°'° 3“"‘“"9-
`13-4, Kltaichijonlshl, Chuo-ku, Sapporo-shl. Hokkaido. 060-0001
`TEL: +81-11-221-2743
`.s‘““' °m°°' T°h°k" Hm G'°""' T°"°'“‘ s°°°“d G'°""
`Take“ Sande‘ 3U‘|d'"9
`2-13-2t H°"°h°- A°b8-'<U- 3°"d='-5h'- M'V89'- 930-0014
`T514 *31'22'254'2233
`
`[saitama Kitakanto Shinetsu Branch]
`Outsunomlya Otflce, Klta-Kanto Group
`Ch“° Um-'"°""Y3 B”"d'"9
`3-1-1. Higashishukugo, Utsunomiya-shi, Tochigi. 321-0953
`TELI +3143-533'525°
`Osaltama Olflce, Saltams Group, Shlnelsu Group
`82 0miY3 Bulldmg
`1-11-3, Sakuragicho, Omiya-ku. Saitama-shn, Sanama. 330-0854
`TE‘-1 *3‘-43-558-234°
`"(auto Branch]
`Qcmba omce. Chlba Group
`Lalaport Milsui Building
`2-1-1. Hamacho. Funabashi-shi. Chiba. 273-0012
`TEL: +81-47-431-1238
`
`[1-okai Bmnchi
`Qnagoya Office, Tokal First Group, Tokal second Group
`Nlshikl Park Building
`2_4_3. Nishiki_ Naka_ku. Nagoyaqhil Aichi_ 4s0_oo03
`TEL: +81_52_211_256o
`Cshlzuoka Satellite Ofllce. Tokal First Group (shlzuoka base)
`Mltsul Selma! Shlzuoka-eklmae Building
`11-7. Kuroganecho. Aoi-ku. Shizuoka-shi. Shizuoka. 420-0351
`TEL: +81-52-211-2560 (Nagoya Office)
`
`[Kansm Shikoku 3i-anchi
`.Kyoi° °"i¢e_ iiyoio Gmiii,
`Sumitomo Seimei Kyoto Building
`62_ 1-sukihokochoi shinmachihigashiirui Si-iiiodoi-ii
`Shimogyo-ku, Kyoto-shi, Kyoto. 600-8492
`TEL: +81-75-229-6549
`.0saka Office. Osaka Flrst Group. Osaka Second Group
`-i-akeda i.iii.a,i°_maciii Buiiding
`2-4-9, Hirano-machi, Chuo-ku, Osaka, 541-0046
`TEL: +81-S-6226-0403
`."°"° °"'°°-A "°"° _°'°"P
`.
`K°b° “°'“3°f" 3"‘'d'"9
`121- "°'“3°h'- C““°"‘"- K°b°'5"'- ”Y°9°v 55°'°°32
`TE“ "3"73'321'°475
`
`.Tokyo Ofllce, Tokyo First Group, Tokyo Second Group. Tokyo Thlrd Group
`MFPR Niiionbasiiiiioncho Buiding
`3_7_2i Nihonbashihonchol Chu°_kui Tokyo‘ 1o3_o023
`TEL: +a1_3_5643_1 950
`.Yokohama Office, Yokohama Group
`Higashitotsuka West Building
`90-6, Kawakamicho. Totsuka-ku, Yokohama-shi, Kanagawa. 244-0805
`TEL: "51'45'823'1381
`
`5"'k°k" F"‘_’“"
`.7"“"""‘“
`Takamatsu Dalichl Seimei Building.
`1-3-2, KOIODUKICHO, Takamatsu-shl, Kagawa, 750-0023
`TEL: "81-87-822-9492
`[Kyushu Chugoku Branch]
`.Hi,°,iiim, om", ciiuoku Gmii,
`-i-aiieda Himshima Buiiding
`1-25, Komachl, Naka-ku, Hiroshima-shi, Hiroshima, 730-0041
`TEL: +81-82-248-2023
`
`OFukuoka Office. Kyushu Flrst Group. Kyushu Second Group
`Fukuoka Takeda Building
`9-12, Shlmokawabatamachl, Hakaia-ku, Fukuoka-shi, Fukuoka, 812-0027
`TEL: +81-92-271-2390
`
`IManufacturing Plants and Research Laboratories
`
`Omanufacturing Plant Karatsu
`4228-1. lshishl. Karatsu-shl. Saga. 847-0832
`TEL: +81-955-78-1050
`Omanutacturing Plant Fukusakl
`767-7, Saljl, Fukusaklcho, Kanzaki-gun, Hyogo, 679-2285
`TEL: +81-790-22-2671
`
`Okobe creative center
`1-5-4. Murotanl. Nlshl-ku, Kobe-shl. Hyogo. 651-2241
`TEL: +81-78-997-1010
`Osenju Laboratory of Ocular Science
`BMA
`1-5-5, Mlnatojlmaminamlmachl. Chuo-ku, Kobe-shi, Hyogo. 650-0047
`TEL: +81-78-303-4031
`
`PAGE 16 OF 18
`
`

`
`P1'OdllCtS (Overseas)
`
`I Asia
`
`Ichlna
`<>Pranopu|in (Senju)
`Ocatalin (Senju)
`:|Bronuck (Senju)
`Qsodiurn Hyaluronate (Senju)
`~kTalymus (Senju)
`
`Isoutli Korea
`<)Pranopu|in (JW Shinyak)
`‘nvLomefIon (JW Shinyak)
`OTimobetaIol-LA (Taejoon)
`;]Bronuck (Taejoon)
`Isenju CL (JW Pharma)
`IFrenz Eye Drops (JW Pharma)
`
`Illong Kong
`Ccatalin (Takeda Hong Kong)
`
`ITalwan
`Ocatalin K (Takeda Taiwan)
`
`IPhl|lppInu
`Ocatalin (Takeda Philippines)
`
`Ilndonula
`Ccatalin (P.T. Takeda Indonesia)
`
`ITha||and
`Ccalalin (Takeda Thailand)
`
`IPakl:lan
`Ccetalln (Helix)
`
`IVlotnam
`|_]Bronuck (Senju)
`0Tearbelance (Senju)
`
`Ilndla
`OG|ucotimLA (Centaur)
`Eocubro (Centaur)
`
`
`
`(sn:nua.\(_))swnpmd
`
`I Americas
`
`IUnltod Status
`Olstalol (B+L)
`UProlensa (B+L)
`[—|Bromday (B+L)
`OBepreve (84-L)
`ODurezo| (Alcon)
`
`Ilfloxlco
`<>Niflan (SIFI)
`
`IBrull
`Cclarvisol (Allergan)
`
`IPuarto Rico
`ODurezol (Alcon)
`
`Icanada
`ODurezol (Alcon)
`
`I Europe and the Middle East
`
`IPolInd
`Ocatalin (Pharmaheads)
`:lYeIox (Valeent)
`
`Ikomanla
`<>Pranollog (SIFI)
`
`Iflalglum
`<>Pranox (MEDA)
`
`IPor1u9a|
`Oclarvlsan (LUSO)
`:lYeIox (Valeant)
`
`IINV
`Oclarvisan (Allergen)
`<>Pranoflog (SIFI)
`C|YeIox (Valeant)
`
`Illuula
`Ocatalin (Senju)
`
`IGermany
`jYeI|ox (Valeant)
`
`IUnitId Kingdom
`:]YeI|ox (Valeant)
`
`IAustria
`
`:]Ye||ox (Valeant)
`
`IFram:e
`3YeI|ox (Valeant)
`
`Ilmhorlands
`jYe||ox (Valeant)
`
`Ikepuhlic of Inland
`:Ye||ox (Valeanl)
`
`Isweden
`’ Yellox (valeant)
`
`INorway
`_ Yellox (Valeant)
`
`Iflulgaria
`CYeIox (valeant)
`
`Illungary
`Yelox (Valeant)
`
`Iswitzorland
`_ Yelox (valeant)
`
`IDanmark
`
`Isaudi Arabia
`
`:Ye||ox (Valeanl)
`
`Ocatelin (Saudi Arabian Drug Store)
`
`IFin|and
`:YelIox (Valeant)
`
`Ispaln
`:Ye||ox (Valeanl)
`
`Product names in Japan: . CATALIN fr LOMEFLON O NIFLAN I
`*()=Marketing Authorization Holder
`
`I BRONUCK O TEARBALANCE t TALYMUS I Generic medicine O Nol sold in Japan
`
`As of July 2015
`
`PAGE 17 OF 18
`
`

`
`Products (Japan)
`
`I Prescription Products
`
`[Eye products]
`Inflammation and allergy
`ELICS OPHTHALMIC SOLUTION 0.25%
`ODOMEL OPHTHALMIC SOLUTION 0.02%
`ODOMEL OPHTHALMIC SOLUTION 0.05%
`ODOMEL OPHTHALMIC SOLUTION 0.1%
`CROMOFERON OPHTHALMIC SOLUTION 2%
`KETAS OPHTHALMIC SOLUTION 0.01%
`NIFLAN OPHTHALMIC SOLUTION 0.1%
`VISUALIN OPHTHALMIC SOLUTION 0.02%
`VISUALIN OPHTHALMIC SOLUT1ON 0.05%
`VISUALIN SOLUTION FOR EYE EAR AND NOSE 0.1%
`BRONUCK OPHTHALMIC SOLUTION 0.1%
`LYSOTEAR OPHTHALMIC SOLUTION 0.5%
`
`LEVOCABASTTNE 0.025% OPHTHALMIC SOLUTION [TS]
`
`Antibacterial and nntifungol agent:
`GATIFLO OPHTHALMIC SOLUTION 0.3%
`BACCIDAL OPHTHALMIC SOLUTION 0.3%
`PIMARICIN 1% Ointment [SENJU]
`PIMARICIN OPHTHALMIC SOLUTION 5% [SENJU]
`BESTRON OPHTHALMIC SOLUTION 0.5%
`LOMEFLON OPHTHALMIC SOLUTION 0.3%
`LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%
`
`Cataracts
`CATALIN FOR OPHTHALMIC 0.005%
`CATALIN-K FOR OPHTHALMIC 0.005%
`
`Glaucoma
`AIPHAGAN OPHTHALMIC SOLUTION 0.1%
`MIKELAN OPHTHALMIC SOLUTTON 1%
`MIKELAN OPHTHALMIC SOLUTTON 2%
`MIKELAN LA OPHTHALMIC SOLUTION 1%
`MIKELAN LA OPHTHALMIC SOLUTION 2%
`LATANOPROST OPHTHALMC SOLUTION 0.005% SENJU
`LUMIGAN OPHTHALMIC SOLUTION 0.03%
`
`surgical aids
`INDOMELOL OPHTIIAUIIC SOLUTION 0.5%
`OXYBIPROCAIE HYDROCILOIIDE IMISOPIITHILIIIC SOLUTION 0.4‘/I [SEiI1J|
`OPEGUARD-MA INTRAOCULAR IRRIGATTNG SOLUTION
`OPEGUARD Nuo I01 IITRAOCULAR RRIGATING SOLUTION 01.118411
`OPELEAD 0.5 OPHTHALMIC VISCOELASTID PREPARATION 1%
`OPELUD 0.6 OPHTHALMIC VISCOELASTIC PREPARATION 1%
`OPELEAD 1.1 OPHTHALMIC VISCOELASTKE PREPARATION 1%
`OPELEAD HVO.¢ OPHTHALIIC VISCOELASTKL PREPARATDN 1%
`OPELEAD HVO.6 OPHTHALIIC VISCOELASTI‘, PREPARATION 1%
`OPHEAD HV085 OPHTHALMIC VISOOELASTIC PREPARATION 1%
`
`
`
`(uvdif)nanpoxd
`
`Other
`ARTTFICIAL TEAR MYTEAR OPHTHALMIC SOLUTION
`SCOPISOL SOLUTION FOR EYE
`SOFTEAR OPHTHALMIC SOLUTION 0.02%
`TAZIN TABLETS 30
`TALYMUS OPHTHALMIC SUSPENSION 0.1%
`TEARBALANCE OPHTHALMIC SOLUTION 0.1%
`TEARBALANCE OPHTHALMIC SOLUTION 0.3%
`TEARBALANCE MINIMS OPHTHALMIC SOLUTION 0.3%
`
`[Ear. nose and throat products]
`VISUALIN SOLUTION FOR EYE EAR AND NOZE 0.1%
`BESTRON FOR EAR AND NOSE 1%
`LOMEFLON SOLUTION FOR EAR 0.3%
`LOMEFLON MINIMS SOLUTION FOR EYE AND EAR 0.3%
`
`I Over the Counter (OTC) Products
`
`Icontact Lens Products
`
`Eye medicine
`Myiaar EYETECT
`Mytear EYETECT ALPITATTO
`Mytear EYETECT ALPITATTO-N
`Mytear ALPITATTO EXa
`Mytear ALPITATTO ~ EXa
`NewMytear A
`Mytearciean Cool
`Mytear Vitamin BaBcE
`Mytaar Vido
`Mytoar FrecM0
`
`Eye medicine for use with contact lens
`NewMytoav CL 1:
`NowMytsar CL Cool a
`NewMytaar CL Cool HI I:
`NewMytear CL Ice Crush
`FirstMytear CLpP
`Firsmytear CL-G
`FirsIMyIaar CL-B
`
`O;/hard use
`Mylar Hard Lonswoaiug Solution (dosignaiud quasi-drug)
`NewMytear Easy S
`NewMyIear CL 0: Lens Cam
`
`IAnImal Medicines
`
`IAnImaI Quasi-Drugs
`
`I Animal Health Products
`
`STEROP
`TEAROSE
`PAPITEIN
`MIMIENA
`UGHT CLEAN
`LOMEWON
`ONE CLEAN
`
`PAGE 18 OF 18
`
`BEST FRIENDS EAR CLEANER A
`BEST FRIENDS EAR CLEANER G
`
`BEST FRIENDS RINSE IN SHAMPOO
`BEST FRIENDS TREATMENT MIST TYPE
`
`As of July 2015